AU2002251054A1 - Triazole compounds and the use thereof in the prophylaxis and therapy of neurodegenerative diseases, cerebral trauma and cerebral ischemia - Google Patents

Triazole compounds and the use thereof in the prophylaxis and therapy of neurodegenerative diseases, cerebral trauma and cerebral ischemia

Info

Publication number
AU2002251054A1
AU2002251054A1 AU2002251054A AU2002251054A AU2002251054A1 AU 2002251054 A1 AU2002251054 A1 AU 2002251054A1 AU 2002251054 A AU2002251054 A AU 2002251054A AU 2002251054 A AU2002251054 A AU 2002251054A AU 2002251054 A1 AU2002251054 A1 AU 2002251054A1
Authority
AU
Australia
Prior art keywords
cerebral
prophylaxis
therapy
neurodegenerative diseases
triazole compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002251054A
Inventor
Berthold Behl
Francisco Javier Garcia-Ladona
Kurt Schellhaas
Dorothea Starck
Gerd Steiner
Laszlo Szabo
Liliane Unger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Publication of AU2002251054A1 publication Critical patent/AU2002251054A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
AU2002251054A 2001-03-01 2002-02-28 Triazole compounds and the use thereof in the prophylaxis and therapy of neurodegenerative diseases, cerebral trauma and cerebral ischemia Abandoned AU2002251054A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10109866.9 2001-03-01
DE10109866A DE10109866A1 (en) 2001-03-01 2001-03-01 Triazole compounds and their use for the prophylaxis and therapy of neurodegenerative diseases, brain trauma and cerebral ischemia
PCT/EP2002/002202 WO2002069972A2 (en) 2001-03-01 2002-02-28 Triazole compounds and the use thereof in the prophylaxis and therapy of neurodegenerative diseases, cerebral trauma and cerebral ischemia

Publications (1)

Publication Number Publication Date
AU2002251054A1 true AU2002251054A1 (en) 2002-09-19

Family

ID=7675936

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002251054A Abandoned AU2002251054A1 (en) 2001-03-01 2002-02-28 Triazole compounds and the use thereof in the prophylaxis and therapy of neurodegenerative diseases, cerebral trauma and cerebral ischemia

Country Status (3)

Country Link
AU (1) AU2002251054A1 (en)
DE (1) DE10109866A1 (en)
WO (1) WO2002069972A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005037286A1 (en) 2003-03-25 2005-04-28 Vasopharm Biotech Gmbh Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
EP1928846B1 (en) 2005-08-18 2014-06-04 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EP2118077B1 (en) 2007-02-08 2014-12-24 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8810748D0 (en) * 1988-05-06 1988-06-08 Beecham Wuelfing Gmbh & Co Kg Novel treatment
DE4425144A1 (en) * 1994-07-15 1996-01-18 Basf Ag Triazole compounds and their use
FR2723091B1 (en) * 1994-07-29 1996-11-08 Esteve Labor Dr TETRAHYDROPYRIDINE- (6,4-HYDROXYPIPERIDINE) ALKYLAZOLES
DE19600934A1 (en) * 1996-01-12 1997-07-17 Basf Ag Substituted aza and diazacycloheptane and cyclooctane compounds and their use
DE19728996A1 (en) * 1997-07-07 1999-01-14 Basf Ag Triazole compounds and their use
DE19922443A1 (en) * 1999-05-07 2000-11-09 Basf Ag Use of dopamine D3 receptor ligands in the manufacture of drugs for the treatment of renal dysfunction
AU2001250404A1 (en) * 2000-03-27 2001-10-08 Basf Aktiengesellschaft Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system

Also Published As

Publication number Publication date
WO2002069972A2 (en) 2002-09-12
DE10109866A1 (en) 2002-09-05
WO2002069972A3 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
AU2001247331A1 (en) Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
AU2002343739A1 (en) Improved therapy for topical diseases
AU2003255993A1 (en) Diazabicyclic compounds useful in the treatment of cns and other disorders
AU5618501A (en) Dihydropyrimidines and the use thereof as medicaments for the treatment of hepatitis
AU2003212634A1 (en) Compounds useful in the treatment of cancer
AU2001260834A1 (en) The treatment of herpes
AU2001233757A1 (en) Novel use of pulmonary surfactant for the prophylaxis and treatment of chronic pulmonary diseases
AU2002319296A1 (en) Use of 2-alkoxyphenyl-substituted imidazotriazinones for the treatment of diseases associated with CGMP regulated processes
AU2002242713A1 (en) Use of triazole compounds for prophylaxis and in therapy for neurodegenerative illnesses, brain traumas and cerebral ischaemia
AU2002251054A1 (en) Triazole compounds and the use thereof in the prophylaxis and therapy of neurodegenerative diseases, cerebral trauma and cerebral ischemia
AU2002350832A1 (en) Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension
AU2002352566A1 (en) Use of corrinoids in the treatment of skin diseases
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
AU2002310922A1 (en) Interferons in the treatment of ischemia
AU2002212489A1 (en) Veterinary composition for the topical treatment of traumatized or inflamed skin
AU2002349013A1 (en) Use of 7h-pyrrolo(2,3-d)pyrimidine derivatives in the treatment of solid tumor diseases
AU2003269257A1 (en) Use of cap-1 for the therapy of asthma
AU2002241162A1 (en) Intimins in the prevention or treatment of infections:ii
AU2001248346A1 (en) Use of CDP-choline for the prophylactic treatment of cerebral ischemia
AU2002344959A1 (en) Use of fasl for the treatment of neurodegenerative diseases
AU2002350513A1 (en) Use of solasonine for the treatment of skin tumors
AUPQ475499A0 (en) Phosphoglycerate kinase in the treatment of disease
WO2001049298A3 (en) Novel therapeutic use of enoxaparin
AU2002324798A1 (en) Pyrazolo-pyridines for the treatment of herpes infections
AU2002313005B2 (en) Use of glycoprotein for the treatment and re-epithelisation of wounds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase